CMA
55
3
M
42
8
AME
62
3
CB
51
4
TSCO
55
2
MTB
69
5
UNM
59
5
A
48
4
EXC
69
2
USB
68
4
LB
46
-7
CTAS
64
2
IRM
44
2
ZTS
38
5
HPQ
59
2
MA
67
7
MAT
58
3
PM
83
4
O
44
5
MET
67
6
CMA
55
3
M
42
8
AME
62
3
CB
51
4
TSCO
55
2
MTB
69
5
UNM
59
5
A
48
4
EXC
69
2
USB
68
4
LB
46
-7
CTAS
64
2
IRM
44
2
ZTS
38
5
HPQ
59
2
MA
67
7
MAT
58
3
PM
83
4
O
44
5
MET
67
6
Financhill
Back

MoonLake Immunotherapeutics Stock Predictions

This Company Didn't Survive the AI Reset-It Triggered It. You Can Still Get In Early.

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering. Please read the offering circular and related risks at invest.radintel.ai. *RAD Intel recently received their ticker reservatio
Sell
44

MLTX
MoonLake Immunotherapeutics

Last Price:
$38.17
Seasonality Move:
49.62%

7 Day Trial

ALL ACCESS PASS

$ 7

10 stocks to buy for the next leg of this rally

Get the full list here FREE

MoonLake Immunotherapeutics Stock Forecast

  • Over the next 52 weeks, MoonLake Immunotherapeutics has on average historically risen by 103.5% based on the past 4 years of stock performance.
  • MoonLake Immunotherapeutics has risen higher in 2 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
  • Is MoonLake Immunotherapeutics Stock Undervalued?
    The current MoonLake Immunotherapeutics [MLTX] share price is $38.58. The Score for MLTX is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.
  • MLTX is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will MoonLake Immunotherapeutics Stock Go Up Next Year?

  • Over the next 52 weeks, MoonLake Immunotherapeutics has on average historically risen by 103.5% based on the past 4 years of stock performance.

MoonLake Immunotherapeutics Stock Rating

Sell
44
MoonLake Immunotherapeutics (MLTX) is a Sell

Is MoonLake Immunotherapeutics overpriced?

  • MoonLake Immunotherapeutics has risen higher in 2 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%

MoonLake Immunotherapeutics Stock Price History

Is MLTX stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and MLTX is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Switzerland
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
moonlaketx.com

52-Week Data

52-Week High:
58.26
52-Week Low:
31.42

Prediction Charts

Market Cap:
2.4B
Price in USD:
38.58
Volume:
169.2K
Beta:
1.32

Technical Analysis

SMA50:
38.63
SMA100:
41.65
SMA200:
45.82
52-Wk Change:
-5.56%

Stock Predictions

  • Is MoonLake Immunotherapeutics stock public?
    Yes, MoonLake Immunotherapeutics is a publicly traded company.
  • What is the MoonLake Immunotherapeutics stock quote today?
    The MoonLake Immunotherapeutics stock price is 38.58 USD today.
  • How to buy MoonLake Immunotherapeutics stock online?
    You can buy MoonLake Immunotherapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
May-7 39.43 37.60 39.43 37.05
May-8 37.70 39.74 40.12 36.75
May-9 39.74 38.47 40.75 38.07
May-12 39.17 40.18 40.86 39.17
May-13 40.58 38.54 41.10 38.31
May-14 38.66 36.99 39.50 36.35
May-15 36.98 37.66 37.76 36.05
May-16 37.65 37.62 38.31 36.69
May-19 38.85 39.20 40.49 37.76
May-20 39.39 40.28 40.43 39.12
May-21 39.83 38.54 40.22 38.47
May-22 38.21 38.51 38.79 37.79
May-23 38.01 38.93 39.08 37.92
May-27 39.71 38.58 40.71 38.41

MoonLake Immunotherapeutics Earnings

MoonLake Immunotherapeutics Earnings Report: Per Share MoonLake Immunotherapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.

MoonLake Immunotherapeutics Forecast Revenue Growth

MoonLake Immunotherapeutics Stock Analysis: Historical quarterly revenues per share for MoonLake Immunotherapeutics and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.33 per share, a decrease next quarter of $0.11 per share, a decrease this year of $1.24 per share, and a decrease next year of $0.58 per share.

* MoonLake Immunotherapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.